A Vendor-Sponsored Trial Says Every-Other-Day CHG Is Fine: Now What?
A staff nurse brings you a single randomized trial, funded by a manufacturer of chlorhexidine wipes, that compared daily with every-other-day chlorhexidine bathing in 200 ICU patients and found no difference in central line-associated bloodstream infection (CLABSI; 3 versus 4 events). She asks whether the unit should switch to save money: estimated $18,000 per year. Your unit's baseline CLABSI rate is 0.9 per 1,000 line-days; daily CHG bathing compliance is 91%; current policy is daily. The nurse manager is enthusiastic about the savings and wants an answer by Friday.
1. Formulate the clinical question and appraise the study's internal validity. What would make you cautious about its conclusion?
Read the worked answer
PICO: In adult ICU patients with central venous catheters, does every-other-day chlorhexidine bathing compared with daily bathing reduce CLABSI, mortality, and cost without increasing skin complications?
Appraisal cautions:
- Event rate and power: 3 versus 4 events in 200 patients is a tiny number. The study is almost certainly underpowered; a wide confidence interval may include a clinically important benefit for daily bathing. 'No difference' may mean 'not enough events to tell.'
- Randomization and allocation concealment: were they adequate, and were assessors blinded?
- Single center and a short follow-up limit generalizability.
- Funding and conflict of interest: manufacturer funding does not invalidate the study, but it raises the bar for scrutiny.
- Adherence and co-interventions: were both groups bathed as assigned, and were other bundle elements equal?
- Outcome definition: CDC/NHSN CLABSI definitions, and whether secondary infections were captured.
Bottom line: a single small industry-funded trial is not enough to overturn a guideline-supported daily bathing policy, especially when the baseline event rate is low and the absolute difference is fragile.
2. Would you recommend changing policy now? Explain the evidence hierarchy and local context factors.
Read the worked answer
No change now. Recommend a formal evidence review before Friday: current SHEA/IDSA guidance, systematic reviews, and the hospital's own CLABSI data. The nurse manager's $18,000 estimate is real, but one CLABSI often costs far more than that in attributable mortality, length of stay, and reimbursement penalties.
Consider the local context:
- Compliance is 91%, not 100%; closing that gap may matter more than changing frequency.
- The unit's rate is already low (0.9), which makes a frequency change hard to evaluate and risky to adopt.
- Daily bathing is embedded in a bundle; changing one element without testing the whole bundle is a systems error.
What I would say to the manager: 'The question is legitimate, but a single small trial cannot answer it. Let's do a rapid review and bring it to infection prevention. If the evidence is genuinely equivocal, we can consider a monitored pilot, not a policy switch.' This respects the nurse's inquiry while protecting patients from a premature cost-driven change.
3. How would you engage the nurse and the manager in evidence-based practice and design a learning plan?
Read the worked answer
Engage rather than dismiss. Thank the nurse for bringing evidence forward; that behavior is exactly what a clinical inquiry culture needs. Offer to co-lead the appraisal with her, the infection preventionist, and a librarian.
Learning plan:
- A 30-minute journal club on asking answerable questions, appraising randomized trials, and understanding power and confidence intervals.
- Teach the difference between 'no evidence of difference' and 'evidence of no difference.'
- Use the unit's own data to make the lesson concrete: catheter days, CLABSI events, compliance audits.
- Invite infection prevention to present the bundle rationale, and have the manager present the cost trade-off transparently.
- Set a 3-month evaluation plan with process and outcome measures, including skin integrity and cost.
Facilitation of learning principle: do not use hierarchy to end the conversation. The goal is a staff nurse who can appraise the next study and a manager who can weigh cost against harm. If the evidence review supports a pilot, design it with clear stopping rules; if not, explain why and publish the decision.